Clinical Trials Browser

Phase 3 × Myelodysplastic Syndromes × luspatercept × Clear all

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT02631070 2021-12-17

MEDALIST

Phase 3 Completed

229 enrolled 36 charts 2 FDA

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes